Phibro Animal Health | PAHC - 销售成本

金融业

USD

USD 1.45B

现金及等价物

USD 54.93M

USD 240.42M

USD 894.07M

USD 281.87M

USD 474.17M

股息收益率

1.29

USD 54.99M

USD 68.1M

1.92K

EPS每股收益

USD 0.78

股本和储备

USD 361.83M

USD 133.5M

债务利息支出

USD 11.91M

USD 0.08

USD 597.69M

USD 1.45B

USD 27.46M

USD 361.83M

USD 54.99M

普通股股本

USD 40.48M

13.82

USD 38.63M

USD 373.91M

销售和管理费用

USD 78.32M

USD 539.7M

贸易债权人

USD 129.64M

应收帐款人

USD 215.87M

	销售成本	更改		日
Align Technology	USD 298.76M		4.74M	2026-06
ANI Pharmaceuticals	USD 119.8M		5.3M	2026-06
Aurora Cannabis	CAD 8.22M		80.38M	2026-03
Bristol-Myers Squibb	USD 7.89B		4.03B	2026-06
Canopy Growth	CAD 62.98M		9.91M	2026-03
Corcept Therapeutics	USD 4.06M		1.18M	2026-06
Eli Lilly	USD 3.27B		309M	2026-06
Henry Schein	USD 2.43B		129M	2026-06
Idexx Laboratories	USD 437.5M		19.42M	2026-06
Knight Therapeutics	CAD 82.22M		1.03M	2025-12
Merck	USD 3.14B		200M	2026-06
Nektar Therapeutics	USD 4.43M		5.3M	2024-09
Pacira	USD 58.49M		7.75M	2026-06
Phibro Animal Health	USD 240.42M		2.58M	2025-12
Prestige Brands	USD 135.22M		5.54M	2026-06
Supernus Pharmaceuticals	USD 59M		9.97M	2026-06
Zoetis	USD 704M		32M	2026-06